458 STATIN USE AND RISK OF PROSTATE CANCER IN A POPULATION OF MEN SCREENED FOR PROSTATE CANCER

You have accessJournal of UrologyProstate Cancer: Epidemiology and Natural History1 Apr 2011458 STATIN USE AND RISK OF PROSTATE CANCER IN A POPULATION OF MEN SCREENED FOR PROSTATE CANCER Nelly Tan, Eric Klein, Jianbo Li, Ayman Moussa, and J. Stephen Jones Nelly TanNelly Tan Cleveland, OH More articles by this author , Eric KleinEric Klein Cleveland, OH More articles by this author , Jianbo LiJianbo Li Cleveland, OH More articles by this author , Ayman MoussaAyman Moussa Cleveland, OH More articles by this author , and J. Stephen JonesJ. Stephen Jones Cleveland, OH More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.551AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Statin Use and Risk of Prostate Cancer in a Population of Men Screened for Prostate Cancer. METHODS We performed a retrospective nested case-control study of men utilizing an IRB-approved prostate biopsy database of patients who underwent prostate biopsy from 1997–2007 at Cleveland Clinic. Statin use was determined by using outpatient pharmacy records. Clinical variables collected were patient age, African American race, DRE status, BMI, serum PSA and prostate volume. Pathologic information collected from the EMR pathology report included biopsy Gleason sum (GS), number of cores obtained and number of cores positive. RESULTS We analyzed data from 4204 patients, of which we identified a total of 3182 (75.7%) patients not on statins and 1022 using statins. In a univariate analysis, men diagnosed with PC on statins compared to patients not taking statins were less likely to have DRE positivity (5.3% vs 8.9%, OR 0.7, p<0.01), GS 7 or greater prostate cancer (61.4% vs. 72.4%, OR 0.78, p=0.02), and high volume prostate cancer (27.2 vs 31.4, p<0.01). Median PSA was lower in men being screen for PC on statins compared to men not on statins (5.13 vs 5.98, p= 0.03). Multivariate analysis demonstrated sustained protective associations of statins and prostate cancer (Figure 1). The adjusted odds ratio for prostate cancer diagnosis, high grade prostate cancer (GS>/=7), >/=3 cores positivity for statin users based on length of statin use were 0.77 (95% CI 0.63–0.93), 0.57 (95% CI 0.47–0.69), 0.78 (95% CI 0.64–0.95) for ever-statin use; 0.77 (95% CI 0.63–C 0.95), 0.59 (95% CI 0.48–0.71), and 0.80 (95% CI 0.66–0.99) for 0–5 years of statin use; 0.86 (95% CI 0.55–1.35), 0.57 (95% CI 0.37–0.90), and 0.73 (95% CI 0.46–1.15) for >5 years of statin use. Patients on statins ever were less likely to have prostate cancer OR 0.77 (0.63–0.93), high grade prostate cancer OR 0.57 (CI 0.47–0.69) and >/=3 cores positive OR 0.78 (CI 0.64–0.95), and all of these associations persisted with the length of statin use. CONCLUSIONS Statin use was associated with decreased risk of prostate cancer, less frequent high grade cancer and lower volume of cancer suggesting that their use has a protective effect against prostate cancer development and progression. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e186-e187 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Nelly Tan Cleveland, OH More articles by this author Eric Klein Cleveland, OH More articles by this author Jianbo Li Cleveland, OH More articles by this author Ayman Moussa Cleveland, OH More articles by this author J. Stephen Jones Cleveland, OH More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Topic: Cancer, Lipids, and Metabolism
Subfield: Cancer Research
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences